German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at... Read More
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:... Read More
NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer Prolaris One of Only Two Prognostic Tests Recommended for Expanded Indications SALT LAKE CITY, March 18, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:... Read More
New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy SALT LAKE CITY, Feb. 14, 202... Read More
Myriad Announces Research Collaboration with University of Leeds Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer SALT LAKE ... Read More
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for More than Four Yea... Read More
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy New Study Finds Approximat... Read More
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer [vc_row][vc_column][vc_column_text el_class=" text-corporate"] EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Br... Read More
EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer NICE Decision is a Major Milestone in Expanding Access to Patient... Read More
Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWS... Read More